Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The British Association for Psychopharmacology guidelines specify the scope and target of treatment for bipolar disorder. The second version, like the first, is based explicitly on the available evidence and presented, like previous Clinical Practice guidelines, as recommendations to aid clinical decision making for practitioners: they may also serve as a source of information for patients and carers. The recommendations are presented together with a more detailed but selective qualitative review of the available evidence. A consensus meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from participants and interested parties. The strength of supporting evidence was rated. The guidelines cover the diagnosis of bipolar disorder, clinical management, and strategies for the use of medicines in treatment of episodes, relapse prevention and stopping treatment.

More information
Type

Journal article

Journal

J Psychopharmacol

Publication Date

06/2009

Volume

23

Pages

346 - 388

Keywords

Antidepressive Agents, Antimanic Agents, Antipsychotic Agents, Bipolar Disorder, Combined Modality Therapy, Consensus, Consensus Development Conferences as Topic, Drug Therapy, Combination, Evidence-Based Medicine, Health Planning Guidelines, Humans, Psychotherapy, Recurrence